Results about: colorectal
“My objective? To generate new knowledge, reach the limits, and fight against uncertainty and frustration”
After eight years, Francisco Barriga is ready for a new stage in his scientific career. He says that IRB Barcelona “shaped” him as a scientist and that he “learnt to ask the right scientific questions.” But he also got involved in many outreach activities. “Over the years, I have never met anyone who did not find what we do interesting. We just need to find the right way to talk about it,” he says.
Roger Gomis’ team, in collaboration with another two groups in IRB Barcelona’s Oncology Programme, reveal in Nature Cell Biology the genes and mechanisms that allow liver metastasis to colonize the lung.
The breakthrough introduces a new concept of metastasis from metastasis, which may require a distinct clinical treatment to metastases generated from the primary tumour.
The study has been partially supported by the BBVA Foundation, which provides two IRB groups signing this article with structural funds.
The team headed by Angel Rodríguez Nebreda, ICREA researcher at IRB, identifies for the first time in mice that the p38 MAPK protein is required for the survival and proliferation of colon cancer cells.
In the same study the scientists demonstrate that a p38 inhibitor that has been used in clinical trials for inflammatory diseases shrinks the tumours in mice.
The study, published today in Cancer Cell, has received funding from the BBVA Foundation, the European project InflaCare, the Spanish Government, and the European Research Council (ERC).
Each year about 330,000 Europeans are diagnosed with colorectal cancer, a disease with a mortality rate of 44%. Many of the new treatments fail in clinical assays, and colorectal cancer metastasis is largely incurable
The journal Cancer Cell ranks the article on colon cancer metastasis by Eduard Batlle and Elena Sancho among the best 10 in 2012.